Table 2 Demographic, tumour and treatment characteristics of 1435 women with breast cancer by quintiles of pre-treatment platelet–lymphocyte ratio

From: Utility of pre-treatment neutrophil–lymphocyte ratio and platelet–lymphocyte ratio as prognostic factors in breast cancer

 

Overall

Quintile 1

PLR ⩽100

n =287

Quintile 2 100⩽129

n =287

Quintile 3 129⩽161

n =287

Quintile 4 161⩽215

n =287

Quintile 5

PLR >215

n =287

P a

Multivariable odds ratio b (95% CI)

Age (years), median

52

56

52

51

50

49

<0.001c

1.00 (0.99–1.01)

Race, n (%)

      

<0.001c

 

Chinese

830 (57.8)

117 (40.8)

150 (52.3)

185 (64.5)

193 (67.2)

185 (64.5)

 

1.00

Malay

363 (25.3)

75 (26.1)

84 (29.3)

69 (24.0)

63 (22.0)

72 (25.1)

 

0.64 (0.45–0.91)c

Indian

222 (15.5)

89 (31.0)

49 (17.1)

32 (11.1)

28 (9.8)

24 (8.4)

 

0.41 (0.26–0.66)c

Others

20 (1.4)

6 (2.1)

4 (1.4)

1 (0.3)

3 (1.0)

6 (2.1)

 

1.77 (0.60–5.22)

Tumour size (cm)d, median

3.5

3.0

3.0

3.0

3.5

5.0

<0.001c

0.99 (0.95–1.03)

No. of positive axillary lymph nodes, n(%)

      

0.091

 

0

639 (51.7)

141 (55.1)

148 (57.1)

149 (55.2)

114 (46.7)

87 (42.2)

 

1.00

1–3

285 (23.1)

57 (22.3)

54 (20.8)

63 (23.3)

56 (23.0)

55 (26.7)

 

1.20 (0.82–1.75)

4–9

170 (13.8)

33 (12.9)

34 (13.1)

29 (10.7)

40 (16.4)

34 (16.5)

 

1.55 (0.98–2.46)

⩾10

141 (11.4)

25 (9.8)

23 (8.9)

29 (10.7)

34 (13.9)

30 (14.6)

 

1.74 (1.04–2.92)c

Unknown

200

       

Distant metastasis, n (%)

      

<0.001c

 

None

1222 (86.1)

263 (92.3)

257 (89.5)

259 (91.5)

242 (85.5)

201 (71.5)

 

1.00

Present

197 (13.9)

22 (7.7)

30 (10.5)

24 (8.5)

41 (14.5)

80 (28.5)

 

1.77 (1.09–2.86)c

Unknown

16

       

Grade, n (%)

      

0.600

 

1

83 (7.7)

21 (9.8)

18 (8.1)

20 (9.0)

14 (6.4)

10 (5.2)

 

1.00

2

514 (4.8)

106 (49.3)

106 (48.0)

97 (43.7)

105 (47.9)

100 (51.5)

 

1.80 (0.92–3.53)

3

474 (44.3)

88 (40.9)

97 (43.9)

105 (47.3)

100 (45.7)

84 (43.3)

 

1.40 (0.68–2.88)

Unknown

364

       

Lymphovascular invasion, n (%)

      

0.059

 

None

552 (53.4)

124 (56.1)

127 (58.0)

113 (52.1)

111 (55.0)

77 (44.0)

 

1.00

Present

482 (46.6)

97 (43.9)

92 (42.0)

104 (47.9)

91 (45.0)

98 (56.0)

 

1.08 (0.73–1.59)

Unknown

401

       

Oestrogen receptor status, n (%)

      

0.109

 

Negative

612 (44.9)

110 (40.0)

140 (50.2)

116 (41.6)

124 (46.1)

122 (46.7)

 

1.00

Positive

751 (55.1)

165 (60.0)

139 (49.8)

163 (58.4)

145 (53.9)

139 (53.3)

 

0.80 (0.53–1.19)

Unknown

72

       

Progesterone receptor status, n (%)

      

0.257

 

Negative

617 (51.2)

119 (48.4)

141 (56.2)

119 (47.2)

122 (51.3)

116 (53.5)

 

1.00

Positive

587 (48.8)

127 (51.6)

110 (43.8)

133 (52.8)

116 (48.7)

101 (46.5)

 

1.30 (0.86–1.96)

Unknown

231

       

HER2 status, n (%)

      

0.007c

 

Negative

699 (55.1)

151 (57.9)

151 (57.6)

165 (63.2)

120 (47.6)

112 (48.3)

 

1.00

Positive

456 (36.0)

85 (32.6)

94 (35.9)

78 (29.9)

103 (40.9)

96 (41.4)

 

1.09 (0.78–1.52)

Equivocal

113 (8.9)

25 (9.6)

17 (6.5)

18 (6.9)

29 (11.5)

24 (10.3)

 

0.89 (0.50–1.60)

Unknown

167

       

NLR (median)

2.20

1.50

1.84

2.18

2.56

3.95

<0.001c

2.23 (1.91–2.62)c

Surgery, n (%)

      

<0.001c

—

None

164 (11.4)

24 (8.4)

23 (8.0)

14 (4.9)

34 (11.8)

69 (24.0)

  

Mastectomy

989 (68.9)

194 (67.6)

192 (66.9)

215 (74.9)

209 (72.8)

179 (62.4)

  

BCS

282 (19.7)

69 (24.0)

72 (25.1)

58 (20.2)

44 (15.3)

39 (13.6)

  

Radiotherapy, n (%)

      

0.555

—

Yes

835 (62.3)

169 (62.4)

168 (61.1)

179 (66.5)

159 (59.8)

160 (61.5)

  

None

506 (37.7)

102 (37.6)

107 (38.9)

90 (33.5)

107 (40.2)

100 (38.5)

  

Unknown

94

       

Neoadjuvant chemotherapy, n (%)

      

<0.001c

—

None

1216 (84.7)

260 (90.6)

253 (88.2)

254 (88.5)

236 (82.2)

213 (74.2)

  

Yes

219 (15.3)

27 (9.4)

34 (11.8)

33 (11.5)

51 (17.8)

74 (25.8)

  

Adjuvant chemotherapy, n (%)

      

0.316

-

None

442 (30.8)

103 (35.9)

89 (31.0)

84 (29.3)

82 (28.7)

84 (29.3)

  

Yes

992 (69.2)

184 (64.1)

198 (69.0)

203 (70.7)

204 (71.3)

203 (70.7)

  

Unknown

1

       

Hormone therapy, n (%)

      

0.173

—

None

492 (38.1)

92 (34.7)

105 (40.1)

87 (33.5)

104 (40.9)

104 (41.8)

  

Yes

798 (61.9)

173 (65.3)

157 (59.9)

173 (66.5)

150 (59.1)

145 (58.2)

  

Unknown

145

       
  1. Abbreviations: BCS=breast-conserving surgery; CI=confidence interval; HER2=Human epidermal growth factor receptor 2; NLR=neutrophil–lymphocyte ratio; PLR=platelet–lymphocyte ratio.
  2. aDerived using the χ2-test for categorical variables, and Kruskal–Wallis test for continuous variables.
  3. bDerived using a multivariable logistic regression model on imputed data (using cutoff for PLR=185), showing pooled odds ratios adjusted for age, race, tumour size, lymph node involvement, distant metastasis, grade, lymphovascular invasion, oestrogen receptor status, progesterone receptor status, HER2 status, and NLR.
  4. cStatistically significant.
  5. dTumour size unknown in 86 patients.
Back to article page